{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"100","value":"23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Neutrophil engraftment, related donors"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"100","value":"25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Neutrophil engraftment, unrelated donors"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"354","value":"31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Platelet engraftment, related donors"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"354","value":"35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Platelet engraftment, unrelated donors"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Median number of days to neutrophil and platelet engraftment.","dispersionType":"Full Range","groups":[{"description":"Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.","id":"OG000","title":"Bone Marrow Transplant"}],"paramType":"MEDIAN","populationDescription":"The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. Engraftment data was not collected on the remaining 25 participants. Recipients of related-donor (n=78) and unrelated-donor (n=39) transplants were reported separately.","reportingStatus":"POSTED","timeFrame":"Up to one year","title":"Days to Engraftment","type":"SECONDARY","unitOfMeasure":"days"}